77893-68-6

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Bromo-3-chlorothiophene is utilized as a key intermediate in the production of pharmaceuticals, contributing to the development of new drugs with diverse therapeutic applications. Its unique structure allows for the creation of novel molecular entities with potential medicinal properties.
Used in Agrochemical Production:
In the agrochemical industry, 2-Bromo-3-chlorothiophene serves as a crucial component in the synthesis of various agrochemicals, including pesticides and herbicides. Its incorporation enhances the effectiveness of these products, supporting agricultural productivity and crop protection.
Used in Organic Compounds and Materials Synthesis:
2-Bromo-3-chlorothiophene is employed as a building block in the synthesis of a wide range of organic compounds and materials, such as polymers, dyes, and specialty chemicals. Its unique properties enable the creation of innovative materials with specific characteristics for various applications.
Used in Research and Development:
2-Bromo-3-chlorothiophene is also valuable in research and development settings, where its unique chemical and physical properties are explored for potential applications in new technologies and scientific advancements. Its versatility as a compound allows researchers to investigate its potential uses in various fields.

Upstream product

• 17249-80-8 3-chlorothiophene 

Downstream Products

• 158036-93-2 Methyl 2-(2-(3-chloro)thienylethynyl)-phenylglyoxylate O-methyloxime 
• 147123-67-9 3-chlorothiophene-2-carbonitrile 

Relevant academic research and scientific papers

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME

The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and applicantion of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

PRODUCTION METHOD OF DITHIENOBENZODITHIOPHENE

PROBLEM TO BE SOLVED: To provide an efficient production method of dithienobenzodithiophene and its derivatives which imparts high carrier mobility by application and enables easy and efficient film production of an organic semiconductor layer. SOLUTION: A production method of dithienobenzodithiophene is characterized by producing dithienobenzodithiophene by using 2,3-dihalothiophene whose halogen at 2-position is equal in atomic number to, or larger than, the halogen at 3-position. COPYRIGHT: (C)2016,JPOandINPIT

4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 al-kyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, halo C1-4 alkyl, CN, C1-C6, alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, ben-zyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z to-gether can be absent

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula: (I); or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α or combinations thereof.

Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay.

Novel aminophenyl ketone derivatives

Novel heteroaryl aminophenyl ketone derivatives which are inhibitors of MAP kinases, in particular the p38 MAP kinase, are useful as anti-inflammatory agents in the prophylaxis or treatment of inflammatory diseases or conditions.